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Summary:
While the 5 year global survival rates for Hodgkin Lymphoma patients
are  beyond  93%,  the  toxicity  of  the  treatment  is  a  major  problem.  We
performed a study that aims to identify prognostic factors at diagnosis that
could suggest more or less aggressive treatment protocols. In this population,
the 5  years overall  survival  rate  was 93,8%, while  the 5 years event-free
survival was 86,7%. Advanced stages, involvement of more than one site at
diagnosis, extranodal disease and the delay on sending the patient for the
specialist were identified as prognostic factors.
Introduction:
Lymphomas are the third most incident cancer in American children (14,6%), and the
second in Brazil  (15,5%)1.  Hodgkin’s lymphoma (HL) is the sixth diagnose in all  pediatric
cancers. While the 5 year global survival rates are beyond 93%², the toxicity of treatment is a
major problem.
Children  treated  for  HL have  10  to  80  times  higher  risk  to  develop  leukemia  or
mielodysplasia than the non-treated population3,4,5, and an important number of patients die
from  cardiovascular  complications6.  Infertility,  solid  tumors,  failure  to  thrive,  thyroid  and
cardiac failure are important late complications of the tratment3,5.
Methods:
We performed a review of all pediatric HL cases treated from 1982 to 2005 in 2 major
pediatric cancer treatment centers in Curitiba, Brazil (Clinicas Hospital of Federal University of
Paraná  and  Erasto  Gaertner  Hospital).  The  study  aims  to  identify  prognostic  factors  at
diagnosis that could suggest more or less aggressive treatment protocols. Patients still  in
treatment  or  previously  treated  in  another  service  were  excluded.  For  prognostic  factors
analysis, 21 patients were excluded because their treatment finished less than 5 years ago.
The data was analyzed by Epi-info software, and the research was approved by the Clinicas
Hospital Human Research Ethics Committee.
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Results:
Of the 169 patients initially analyzed, 49 were excluded (28%). Previous treatment in
another  service  was responsible  for  45% of  the exclusions.  The  background data of  the
participants is shown in Table 1. 
Chemotherapy was administered in 96% of the patients, 34% with ABDV protocol,
20% OPPA and 11% MOPP. Radiotherapy was associated in 86,6% of the cases, 75% with
enlarged field. The 5 years overall survival rate (OS) was 93,8% (Fig 1), while the 5 years
event-free survival (EFS) was 86,7% (Fig 2). 
Univariable analysis of factors predicting treatment failure is shown in Table 2. Age,
sex, histopathology, presence of B symptoms, bulky mediastinal disease or any bulky disease
and hemoglobin level at diagnosis couldn’t statistically predict local failure. Treatment-related
factors, including the type of chemotherapy and association of radiotherapy, did not predict for
local treatment failure as well. The risk of local failure was three-fold higher for patients with III
and IV Ann Harbor stages (23,3%) than for those with stages I and II (7,1%; P = .006; Fig 3).
Thirteen of 67 patients with involvement of more than 1 site at diagnosis experienced relapse
in 5 years (19,4%), six-fold higher risk than those with just 1 site involved (3,1%. P = .03; Fig
4). The sending for a specialist by the local pediatrician was delayed more than 12 months for
13 patients. The relapse in this group was 3-fold higher (30,8%) compared with those who
were immediately sent (11,6%; P = .03).
Multivariable analysis of prognostic factors that independently predicted local failure
revealed that extranodal disease (p=0,0189) and involvement of more than 1 site at diagnosis
(p=0,0488) were significant predictors of local failure.
Discussion:
The data in our study confirmed a developing country pattern of HL (epidemiological
type 1), characterized by a high incidence of mixed cellularity histological subtype. Median
age was slightly lower than in developed countries, although higher than developing countries
reports7. 
Treatment  protocol  in  children  with  HL  involves  the  combined  use  of  multidrug
chemotherapy and associated radiotherapy. The OS and EFS in 5 years were 93,8% and
86,7%, respectively. In Turkey, Oguz et al reported 96,2% and 90,7% rates (respectively) in a
small  population analysis7,  while  in  U.S.A,  Krasin  et  al  reported  93,1% and 83,8% rates
(respectively)  in  a  195  patients  cohort2.  Despite  the high  proportion  of  treatment  failures
among  patients  who  experienced  disease  recurrence,  the  overall  incidence  of  treatment
failure was low.
The goals of the treatment continue to be to reduce therapy and toxicity for patients
with favorable presentation of the disease. The identification of prognostic factors at diagnosis
and the adaptation of therapy according to the disease’s response to initial treatment is the
standard of care2. In pediatric patients, Smith et al.8 revealed that male gender, stage IIB, IIIB,
or IV disease, bulky mediastinal disease, hemoglobin <11.0 g/dl and WBC = 11.5 x 103/mm3
were  factors  that  independently  predict  inferior  EFS  and  OS  rates.  For  Oguz  et  al. 7,
pretreatment  factors  influencing  the  5-year  EFS  which  were  determined  by  univariable
analysis  were  stage,  number  of  involved  nodal  sites,  extranodal  disease,  and  initial
hemoglobin level <11 g/dl. In developed countries, the St. Jude group reported that any bulky
disease, bulky mediastinal disease, hemoglobin < 11mg/dL and Erythrocyte sedimentation
rate > 50 predict local treatment failure in univariable analisys2.
In our study Ann Harbor stages III and IV, number of involved nodal sites at diagnosis
and  late  specialist  evaluation  predict  treatment  failure  in  univariable  analysis.  Ann–Arbor
classification describing the anatomic distribution and thus dissemination of tumor cells has
been demonstrated to be of prognostic relevance for EFS in several studies. Furthermore,
there is consensus about the pronounced prognostic impact of dissemination of HD according
to Ann Arbor classification7.  Stages III  and IV are related to more nodal sites involved at
diagnosis (r=0,448; p<0,0001; Pearson’s relation).
In  multivariable  analysis,  the number of  involved nodal  sites and the presence of
extranodal disease independently predict treatment failure. Both are related to extension of
disease, and are found to be prognostic factors in literature2,7,8,9,10.
However,  age,  sex,  histopathology,  presence  of  B  symptoms,  bulky  mediastinal
disease or any bulky disease and hemoglobin level were not identified as prognostic factors.
This suggests that the success of the adaptation of the treatment protocols annuls the worse
prognosis of the variables11.
The  median  time  from the  first  symptoms  and  the  specialist  evaluation  was  7.4
months. This data suggests low suspicion by the local pediatricians, since the average time to
evaluation in our centers is less than 1 week. As university centers, we are working with local
public health system to encourage local physicians to promptly refer suspicious cases to an
oncology/hematology center.
Different of other studies, the delay on sending the patient to an specialist evaluation
proved to be an important prognostic factor, that  can be fixed with concerted educational
actions. 
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FIG. 1 – 5 YEAR OVERALL SURVIVAL
FIG. 2 – 5 YEAR EVENT-FREE SURVIVAL
FIG. 3 – MULTIVARIATE ANALYSIS: ANN HARBOR STAGE AS PROGNOSTIC FACTOR
FIG. 4 – NUMBER OF INVOLVED SITES
TABLE 1
Characteristic No. of patients % % %
Age, years
≤ 7 33 27.5 - 32.0
> 7 87 72.5 - 67.0
Sex
Male 84 70.0 58.0 77.0
Female 36 30.0 42.0 23.0
Histologic type
Mixed cellularity 47 39.1 18.0 38.0
Nodular sclerosis 42 35.0 70.8 37.0
Lymphocyte predominant 20 16.6 9.2 20.0
Lymphocyte depletion 5 4.1 - 5.0
Not specified 6 5.0 2.0 0.0
Ann Arbor stage
I 16 13.3 18.0 12.0
II 52 43.3 44.6 43.0
III 38 31.6 18.0 35.0
IV 14 11.6 19.4 10.0
Systemic “B” symptoms
Present 56 46.6 29.7 40.0
Absent 64 53.3 70.3 60.0
Envolved sites at diagnosis
1 38 31.7 - -
>1 82 68.3 - -
Extranodal disease
Yes 58 48.3 20.5 66.0
No 62 51.6 79.5 34.0
Any bulky disease
Yes 47 39.1 48.7 26.0
No 73 60.8 51.3 74.0
Bulky mediastinal disease
Yes 20 16.6 31.3 12.0
No 100 83.3 68.7 88.0
Chemotherapy
ABVD 40 33.3 - -
OPPA 24 20.0 - -
MOPP 13 10.8 - -
Other 38 31.6 - -
No 5 4.1 - -
Radiotherapy
Envolved field 30 25.0 - -
Enlarged field 74 61.6 - -
No 16 13.3 - -
Hemoglobin (g/dL)
<11 65 54.1 - 40.0
≥11 54 45.0 - 60.0
Not specified 1 0.83 - 0.0
Specialist sending delay
<12 months 91 72.4 - -
≥12 months 29 27.6 - -
Table 1. Characteristics of 120 pediatric patients with 
Hodgkin´s Lymphoma
Krasin et al. 
n=195 
Oguz et al. 
n=65 
TABLE 2
Characteristic No. of patients % EFS 5a p
Age, years
0,52≤ 7 21 21% 19
> 7 78 79% 66
Sex
0,84Male 69 70% 59
Female 30 30% 26
Histologic type
0,59
Nodular sclerosing 28 28% 22
Mixed cellularity 43 43% 38
Lymphocyte predominant 18 18% 17
Lymphocyte depletion 4 4% 3
Ann Arbor stage
<0,01* 
I 13 13% 13
II 43 43% 39
III 34 34% 28
IV 9 9% 5
Systemic “B” symptoms
0,14Present 46 46% 37
Absent 53 54% 48
Envolved sites at diagnosis
<0,05* 1 32 32% 31
>1 67 68% 54
Extranodal disease
0,77Yes 46 46% 39
No 53 54% 46
Any bulky disease
0,58Yes 41 41% 36
No 58 59% 49
Bulky mediastinal disease
0,53Yes 16 16% 13
No 83 84% 72
Hemoglobin (g/dL)
0,07<11 42 42% 33
≥11 57 58% 52
Specialist sending delay
<0,05* <12 months 86 87% 76
≥12 months 13 13% 9
Table 2. Incidence of treatment failure in 99 patients with Hodgkin 
Lymphoma¹
¹For prognostic factors analysis, 21 patients were excluded because their treatment 
finished less than 5 years ago.
